Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response

Virology Journal

Volumn 4, Issue , 2007, Pages

  Meyer, Manuela F ^a   Lehmann, Marc ^b   Cornberg, Markus ^a   Wiegand, Johannes ^a   Manns, Michael P ^a   Klade, Christoph ^c   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Jugendanstalt Hameln ^*  (Germany)

^c INTERCELL AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RNA; TETRAMER; GAMMA INTERFERON; VIRUS RNA;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC PATIENT; CLEARANCE; CONTROLLED STUDY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; OFFENDER; PATIENT IDENTIFICATION; SCREENING; SEROCONVERSION; SEX DIFFERENCE; VIREMIA; BLOOD; CD8+ T LYMPHOCYTE; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

HEPATITIS C VIRUS; PAN;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON TYPE II; MALE; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIREMIA;

EID: 34447298368     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-58     Document Type: Article

References (37)

1. T cell failure in hepatitis C virus infection. E Barnes G Lauer B Walker P Klenerman, Viral Immunol 2002 15 285 293 10.1089/08828240260066233 12081013
2. Immunology of hepatitis B virus and hepatitis C virus infection. B Rehermann M Nascimbeni, Nature Reviews Immunology 2005 5 215 229 10.1038/nri1573 15738952
3. Analysis of a successful immune response against hepatitis C virus. S Cooper AL Erickson EJ Adams J Kansopon AJ Weiner DY Chien M Houghton P Parham CM Walker, Immunity 1999 10 439 449 10.1016/S1074-7613(00)80044-8 10229187
4. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. AL Erickson Y Kimura S Igarashi J Eichelberger M Houghton J Sidney D McKinney A Sette AL Hughes CM Walker, Immunity 2001 15 883 895 10.1016/S1074-7613(01)00245-X 11754811
5. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. R Thimme J Bukh HC Spangenberg S Wieland J Pemberton C Steiger S Govindarajan RH Purcell FV Chisari, Proc Natl Acad Sci U S A 2002 99 15661 15668 12441397 10.1073/pnas.202608299
6. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. F Lechner NH Gruener S Urbani J Uggeri T Santantonio AR Kammer A Cerny R Phillips C Ferrari GR Pape P Klenerman, Eur J Immunol 2000 30 2479 2487 10.1002/1521-4141(200009)30:9<2479::AID- IMMU2479>3.0.CO;2-B 11009080
7. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. A Takaki M Wiese G Maertens E Depla U Seifert A Liebetrau JL Miller MP Manns B Rehermann, Nat Med 2000 6 578 582 10.1038/75063 10802716
8. Analysis of successful immune responses in persons infected with hepatitis C virus. F Lechner DK Wong PR Dunbar R Chapman RT Chung P Dohrenwend G Robbins R Phillips P Klenerman BD Walker, J Exp Med 2000 191 1499 1512 10.1084/jem.191.9.1499 10790425
9. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. NH Gruener F Lechner MC Jung H Diepolder T Gerlach G Lauer B Walker J Sullivan R Phillips GR Pape P Klenerman, J Virol 2001 75 5550 5558 11356962 10.1128/JVI.75.12.5550-5558.2001
10. Determinants of viral clearance and persistence during acute hepatitis C virus infection. R Thimme D Oldach KM Chang C Steiger SC Ray FV Chisari, J Exp Med 2001 194 1395 1406 10.1084/jem.194.10.1395 11714747
11. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. K Sugimoto J Stadanlick F Ikeda C Brensinger EE Furth HJ Alter KM Chang, Hepatology 2003 37 590 599 10.1053/jhep.2003.50103 12601357
12. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. GM Lauer M Lucas J Timm K Ouchi AY Kim CL Day JS Wiesch G Paranhos-Baccala I Sheridan DR Casson M Reiser RT Gandhi B Li TM Allen RT Chung P Klenerman BD Walker, J Virol 2005 79 12979 12988 16189000 10.1128/JVI.79.20.12979-12988.2005
13. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. S Urbani B Amadei P Fisicaro D Tola A Orlandini L Sacchelli C Mori G Missale C Ferrari, Hepatology 2006 44 126 139 10.1002/hep.21242 16799989
14. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. M Thomson M Nascimbeni MB Havert M Major S Gonzales H Alter SM Feinstone KK Murthy B Rehermann TJ Liang, J Virol 2003 77 862 870 12502802 10.1128/JVI.77.2.862-870. 2003
15. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. JJ Post Y Pan AJ Freeman CE Harvey PA White P Palladinetti PS Haber G Marinos MH Levy JM Kaldor KA Dolan RA Ffrench AR Lloyd WD Rawlinson, J Infect Dis 2004 189 1846 1855 10.1086/383279 15122521
16. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. MF Meyer H Wedemeyer M Monazahian J Dreesman MP Manns M Lehmann, Epidemiol Infect 2007 135 2 274 280 10.1017/S0950268806006820 16824250
17. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. SM Kamal A Amin M Madwar CS Graham Q He A Al Tawil J Rasenack T Nakano B Robertson A Ismail MJ Koziel, J Virol 2004 78 12252 12258 15507612 10.1128/JVI.78.22.12252-12258.2004
18. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. P Scognamiglio D Accapezzato MA Casciaro A Cacciani M Artini G Bruno ML Chircu J Sidney S Southwood S Abrignani A Sette V Barnaba, J Immunol 1999 162 6681 6689 10352286
19. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. MJ Koziel DK Wong D Dudley M Houghton BD Walker, J Infect Dis 1997 176 859 866 9333142
20. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. H Wedemeyer E Mizukoshi AR Davis JR Bennink B Rehermann, J Virol 2001 75 11392 11400 11689620 10.1128/JVI.75.23. 11392-11400.2001
21. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. M Lehmann MF Meyer M Monazahian HL Tillmann MP Manns H Wedemeyer, J Med Virol 2004 73 387 391 10.1002/jmv.20103 15170633
22. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. H Wedemeyer XS He M Nascimbeni AR Davis HB Greenberg JH Hoofnagle TJ Liang H Alter B Rehermann, J Immunol 2002 169 3447 3458 12218168
23. Long-term follow-up after successful interferon therapy of acute hepatitis C. J Wiegand E Jackel M Cornberg H Hinrichsen M Dietrich J Kroeger WP Fritsch A Kubitschke N Aslan HL Tillmann MP Manns H Wedemeyer, Hepatology 2004 40 98 107 10.1002/hep.20291 15239091
24. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. A Kubitschke MJ Bahr N Aslan C Bader HL Tillmann C Sarrazin T Greten J Wiegand MP Manns H Wedemeyer, European Journal of Clinical Investigation 2007 37 54 64 10.1111/j.1365-2362.2007.01753.x 17181568
25. Function and fate of HCV-specific CD8+ T cells during interferon-alpha therapy of acute hepatitis C. J Wiegand M Cornberg A Ciner V Schlaphoff P Buggisch E Jaeckel MP Manns W H., Antivir Ther 2007 12 303 316 17591020
26. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. J Wiegand P Buggisch W Boecher S Zeuzem CM Gelbmann T Berg W Kauffmann B Kallinowski M Cornberg E Jaeckel H Wedemeyer MP Manns, Hepatology 2006 43 250 256 10.1002/hep.21043 16440367
27. Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. H Wedemeyer T Berg MP Manns H Hinrichsen G Cholewinska S Zeuzem H Blum V Buerger E Tauber S Jelovcan M Buschle J Frisch C Klade, Journal of Hepatology 2005 42 9 10
28. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. C Firbas B Jilma E Tauber V Buerger S Jelovcan K Lingnau M Buschle J Frisch CS Klade, Vaccine 2006 24 4343 4353 10.1016/j.vaccine.2006. 03.009 16581161
29. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. JT Gerlach HM Diepolder R Zachoval NH Gruener MC Jung A Ulsenheimer WW Schraut CA Schirren M Waechtler M Backmund GR Pape, Gastroenterology 2003 125 80 88 10.1016/S0016-5085(03)00668-1 12851873
30. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. M Wiese F Berr M Lafrenz H Porst U Oesen, Hepatology 2000 32 91 96 10.1053/jhep.2000.8169 10869294
31. Treatment of acute hepatitis C with interferon alfa-2b. E Jaeckel M Cornberg H Wedemeyer T Santantonio J Mayer M Zankel G Pastore M Dietrich C Trautwein MP Manns, N Engl J Med 2001 345 1452 1457 10.1056/NEJMoa011232 11794193
32. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. FG De Rosa O Bargiacchi S Audagnotto S Garazzino G Cariti R Raiteri G Di Perri, J Antimicrob Chemother 2006 57 360 363 10.1093/jac/dki458 16396921
33. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. H Hofer T Watkins-Riedel O Janata E Penner H Holzmann P Steindl-Munda A Gangl P Ferenci, Hepatology 2003 37 60 64 10.1053/jhep.2003.50019 12500189
34. Kinetics of HCV-specific CD4+ and CD8+ T cell responses during and after therapy with pegylated interferon-alfa-2B in patients with acute hepatitis C. J Wiegand N Aslan A Ciner P Buggisch E Jaeckel M Cornberg MP Manns H Wedemeyer, Hepatology 2004 40 256A 256A 10.1002/hep.20291
35. Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. A Potthoff J Sarhaddar J Wiegand R Lichtinghagen C Sarrazin A Ciner J Hadem C Trautwein MP Manns H Wedemeyer, Hepatology Research 2005 31 18 23 10.1016/j.hepres.2004.11.007 15652466
36. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. X Jin G Ogg S Bonhoeffer J Safrit M Vesanen D Bauer D Chen Y Cao MA Demoitie L Zhang M Markowitz D Nixon A McMichael DD Ho, Mol Med 2000 6 803 809 11071274
37. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T- cell response in acute hepatitis C. JT Gerlach HM Diepolder MC Jung NH Gruener WW Schraut R Zachoval R Hoffmann CA Schirren T Santantonio GR Pape, Gastroenterology 1999 117 933 941 10.1016/S0016-5085(99)70353-7 10500077